GMP IPO
📋 Filings Intelligence
About Contact
LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.

-
Filed today
-
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings -

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Parmax Pharma Ltd

Parmax Pharma Q2 FY27 Net Profit Rs. 1729.61 Thousands, Fire Loss Unascertained

RESULTS ▼ Concern Flagged HIGH RISK
📅 Filed on BSE: 16 Nov 2026, 07:30 PM IST  ·  BSE ID: 3addf802-0271-4720-9ee5-279aebdf1538
View Original BSE Filing (PDF)
💡
In Simple Terms
The pharmaceutical company announced a profit for its latest quarter, but also disclosed an unquantified loss from a recent factory fire.
🤖 AI Summary
  • Parmax Pharma reported a Net Profit of Rs. 1729.61 Thousands for the quarter ended September 30, 2026 (Q2 FY27).
  • Revenue from operations for Q2 FY27 stood at Rs. 117042.53 Thousands.
  • A fire incident occurred at the manufacturing facility on September 28, 2026; losses are currently unascertained.
  • Company wrote back debt of Rs. 2.32 Crores, which was included in Other Income.
  • Paid-up equity share capital increased to Rs. 68788.86 Thousands as of September 30, 2026.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Revenue from operations (Q2 FY27)
117042.53 Rs. Thousands
362.48
Net Profit / (Loss) (Q2 FY27)
1729.61 Rs. Thousands
108.32
Total Income (Half Year Ended 30.09.2026)
242523.91 Rs. Thousands
440.09
Net Profit / (Loss) (Half Year Ended 30.09.2026)
23724.53 Rs. Thousands
183.45
Paid-up equity share capital (30.09.2026)
68788.86 Rs. Thousands
83.86
🏢 How This Affects the Company
📈
Business Impact
The fire incident on September 28, 2026, at the manufacturing facility, with unascertained plant machinery, finished goods, and semi-finished material damage, introduces uncertainty regarding future production capacity and sales.
💰
Financial Impact
Net Profit for Q2 FY27 was Rs. 1729.61 Thousands. The write-back of debt amounting to Rs. 2.32 Crores contributed to other income. The financial impact of the fire is not yet reflected in the reported results.
⚙️
Operational Impact
The fire incident directly impacts manufacturing operations. The company has not charged depreciation on clean room and effluent treatment plants during the half year ended September 30, 2026, affecting reported expenses.
⚠️
Risk Impact
The unascertained losses from the fire incident introduce a significant operational and financial risk. The lack of provision for these losses in the current financial statements means future periods may reflect these costs.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required by shareholders based on this filing.
👤
Who Is Affected
Shareholders are affected by the company's financial performance, including the reported net profit and the undisclosed impact of the fire incident on the company's assets and future profitability. Paid-up equity share capital increased to Rs. 68788.86 Thousands.
🔍
Management Signal
Management chose to release results without fully accounting for fire losses, indicating a desire to report on current operations while the assessment is ongoing.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List - track these upcoming events
Next quarterly results — ascertain the impact of fire losses on financials.
Updates on insurance claims and restoration efforts post-fire incident.
Disclosure regarding depreciation policy for the clean room and ETP in future periods.
HIGH RISK Unascertained fire losses, coupled with depreciation policy changes, pose significant financial and operational risks.
💡 Investor Takeaway
Parmax Pharma reported Q2 FY27 net profit of Rs. 1729.61 Thousands, up from a loss of Rs. -20783.66 Thousands in Q2 FY26. However, a fire incident on September 28, 2026, at the manufacturing facility, with unascertained losses, has not been reflected in these results. The company also benefited from a debt write-back of Rs. 2.32 Crores.
⚖️ Strengths & Concerns

✅ Positives

  • Net Profit for Q2 FY27 was Rs. 1729.61 Thousands, marking a shift from a loss of Rs. -20783.66 Thousands in Q2 FY26.
  • Debt write-back of Rs. 2.32 Crores contributed to Other Income, improving the overall financial position.

⚠️ Concerns

  • A fire incident on September 28, 2026, caused damage to plant, machinery, and inventory, with losses yet to be ascertained.
  • Depreciation on clean room and effluent treatment plants was not charged during the half year ended September 30, 2026, potentially understating expenses.
📅 Company Track Record
Parmax Pharma reported a net loss of -41590.82 Rs. Thousands for the full FY26. The current Q2 FY27 profit of 1729.61 Rs. Thousands and half-year profit of 23724.53 Rs. Thousands indicate a reversal of losses, though influenced by a significant debt write-back and pending fire loss assessment.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was Parmax Pharma's net profit in Q2 FY27?
Parmax Pharma reported a Net Profit of Rs. 1729.61 Thousands for the quarter ended September 30, 2026 (Q2 FY27).
What was Parmax Pharma's revenue from operations in Q2 FY27?
Revenue from operations for Parmax Pharma stood at Rs. 117042.53 Thousands for the quarter ended September 30, 2026 (Q2 FY27).
Was there a significant event affecting Parmax Pharma's operations recently?
Yes, a fire incident occurred at Parmax Pharma's manufacturing facility on September 28, 2026, causing damage to plant, machinery, and inventory, with losses yet to be ascertained.
Did Parmax Pharma's equity share capital change in the latest period?
Yes, the paid-up equity share capital of Parmax Pharma increased to Rs. 68788.86 Thousands as of September 30, 2026, from Rs. 37413.00 Thousands as of September 30, 2025.
What was the impact of debt write-back on Parmax Pharma's financials?
Parmax Pharma wrote back debt of Rs. 2.32 Crores (equivalent to 23200 Rs. Thousands), which was included in Other Income for the half year ended September 30, 2026.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again - explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.

Live IPO, GMP and market updates on Telegram

IPO open and close dates, grey market premium moves, subscription figures, allotment and listing days, and the market updates worth knowing about, posted on the channel as they happen.

Join the channel